GlassScriptPhysician profile
Felipe Coronado
NPI 1508920059
$6,150.81
in general payments reported to CMS, 2019-2025
22 companies · $899 in 2025
The $899 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,065 · 2022: $2,281 · 2023: $1,224 · 2024: $682 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,804.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,383.56 | 2021-2025 | |
| Amgen INC. | $785.52 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $550.25 | 2022-2024 | Vtama |
| Genzyme Corporation | $444.20 | 2021-2025 | |
| Janssen Biotech, INC. | $432.02 | 2021-2025 | Tremfya |
| Incyte Corporation | $351.13 | 2022-2025 | Opzelura, Iclusig |
| Leo Pharma INC. | $299.05 | 2022-2025 | Adbry |
| Janssen Scientific Affairs, LLC | $273.06 | 2021-2022 | |
| Galderma Laboratories, L.P. | $226.32 | 2021-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $219.68 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $190.64 | 2022-2023 | Sotyktu |
| Organogenesis INC. | $169.64 | 2022-2023 | Puraply |
| Regeneron Healthcare Solutions, INC. | $168.03 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $166.72 | 2021-2025 | Winlevi |
| Ucb, INC. | $152.94 | 2021-2025 | Bimzelx, Cimzia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $134.89 | 2021-2025 | Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $73.58 | 2023-2025 | Zoryve |
| Organon LLC | $42.82 | 2025 | Vtama |
| Allergan, INC. | $32.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.49 | 2025 | Spevigo |
| Botanix Sb INC | $17.95 | 2025 | Sofdra |
| Glaxosmithkline, LLC. | $13.93 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Coronado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.